{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-058307","form_type":"8-K","ticker":"CBUS","cik":"0001705843","company_name":"Cibus, Inc.","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.213488+00:00","generated_at":"2026-06-18T15:33:26.924245+00:00","sec_items":["2.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Calyxt to merge with Cibus Global in all-stock deal; Q4 revenue nominal, cash $3.5M","bullets":["Merger with Cibus Global: all-stock, Calyxt shareholders to own ~5% of combined company; expected close Q2 2023.","Cash and cash equivalents $3.5M as of Dec 31, 2022; cash runway through Q2 2023 with interim Cibus funding.","Revenue nominal in Q4 2022 vs $1.9M in Q4 2021 due to wind-down of soybean product line.","Total operating expenses $3.4M in Q4 2022 vs $6.6M in Q4 2021, driven by cost reduction actions.","Settlement with technology vendor: received $750K in Q4 2022 and another $750K in Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-058307","json":"https://secwatch.observer/filing/0001193125-23-058307.json","markdown":"https://secwatch.observer/filing/0001193125-23-058307.md","text":"https://secwatch.observer/filing/0001193125-23-058307.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1705843/000119312523058307/0001193125-23-058307-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1705843/000119312523058307/d453226d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T15:33:26.924245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a5bd8a808393aa205d8d3e09e1c956588a016308","claim":"Cibus, Inc. reported financial results for the fourth quarter ended December 31, 2022.","evidence_excerpt":"Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its fourth quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1705843/000119312523058307/0001193125-23-058307-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ea9e4540aa9bedbed9873439b591ce754410c4eb","claim":"Cibus, Inc. reported financial results for the year ended December 31, 2022.","evidence_excerpt":"On March 2, 2023, Calyxt, Inc. (the “Company”) announced its financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1705843/000119312523058307/0001193125-23-058307-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}